Key Takeaways
- “DExit” Movement: There is a widely-reported trend of companies reincorporating out of Delaware into states like Texas, Nevada, and Florida due to recent Delaware court decisions affecting director protections and compensation packages.
- Legislative Responses: Delaware has responded with new statutes to clarify and codify rules around controlling shareholders and board decision-making, but the long-term impact depends on judicial interpretation.
- Texas Business Innovations: Texas has introduced business courts, codified the business judgment rule, and allows companies to set ownership thresholds for shareholder litigation, aiming to provide more certainty and innovation for corporations.
- Review Incorporation Strategy: Board and legal teams should assess current state of incorporation and evaluate potential benefits and risks of moving to Texas, Nevada, or Florida, considering recent legislative and judicial changes.
Author(s)
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…